Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpharadin in breast cancer with bone metastases
NCT01070485Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2010
- Primary completion
- Mar 2011
- Modality
- Radiopharmaceutical
- Countries
- 3
01
Overview
A Phase 2 trial of radium-223 dichloride in breast cancer, bone metastases, sponsored by Bayer. Started Jan 2010; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on NCT01070485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01070485.